146 related articles for article (PubMed ID: 12857569)
21. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
[TBL] [Abstract][Full Text] [Related]
22. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
Takami A; Mochizuki K; Okumura H; Ito S; Suga Y; Yamazaki H; Yamazaki M; Kondo Y; Asakura H; Nakao S
Int J Hematol; 2006 Jan; 83(1):80-5. PubMed ID: 16443558
[TBL] [Abstract][Full Text] [Related]
24. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
Baron F; Sandmaier BM; Storer BE; Maris MB; Langston AA; Lange T; Petersdorf E; Bethge W; Maziarz RT; McSweeney PA; Pulsipher MA; Wade JC; Chauncey TR; Shizuru JA; Sorror ML; Woolfrey AE; Maloney DG; Storb R
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1041-8. PubMed ID: 17697966
[TBL] [Abstract][Full Text] [Related]
25. Safety profile of mycophenolate mofetil: a response.
Busca A; Locatelli F; Falda M
Bone Marrow Transplant; 2001 Apr; 27(8):892. PubMed ID: 11477451
[No Abstract] [Full Text] [Related]
26. Prophylaxis and management of graft-versus-host disease.
Ezzone S
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):45. PubMed ID: 19856580
[No Abstract] [Full Text] [Related]
27. Nonmyeloablative transplants: preclinical and clinical results.
Sandmaier BM; McSweeney P; Yu C; Storb R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):78-81. PubMed ID: 10877058
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ
Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696
[TBL] [Abstract][Full Text] [Related]
29. [Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
Miyoshi T; Kawano-Yamamoto C; Nagashima T; Nagai T; Komatsu N; Muroi K; Ozawa K
Rinsho Ketsueki; 2003 Sep; 44(9):968-70. PubMed ID: 14577320
[TBL] [Abstract][Full Text] [Related]
30. New immunosuppressants in BMT/GVHD.
Basara N; Günzelmann S; Willenbacher W; Fauser AA; Kiehl MG
Transplant Proc; 2001 May; 33(3):2220-2. PubMed ID: 11377507
[No Abstract] [Full Text] [Related]
31. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
32. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy.
Grundmann-Kollmann M; Behrens S; Gruss C; Gottlöber P; Peter RU; Kerscher M
J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):134-6. PubMed ID: 10607334
[TBL] [Abstract][Full Text] [Related]
33. Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD.
Rodriguez R; Nademanee A; Palmer JM; Parker P; Nakamura R; Snyder D; Pullarkat V; Zain J; Smith E; Sahebi F; Patane K; Senitzer D; Chang K; Forman SJ
Bone Marrow Transplant; 2010 Jan; 45(1):205-7. PubMed ID: 19503110
[No Abstract] [Full Text] [Related]
34. Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation.
Wada F; Kondo T; Yamamoto R; Yamagiwa T; Arai Y; Mizumoto C; Kanda J; Kitawaki T; Yamashita K; Takaori-Kondo A
Bone Marrow Transplant; 2022 Jul; 57(7):1198-1200. PubMed ID: 35501566
[No Abstract] [Full Text] [Related]
35. [Mycophenolate mofetil, a possible new immunosuppresant].
Weberová J; Voboril R; Semecký V
Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab.
Unal S; Sag E; Kuskonmaz B; Kesici S; Bayrakci B; Ayvaz DC; Tezcan I; Yalnızoglu D; Uckan D
Pediatr Blood Cancer; 2014 May; 61(5):928-30. PubMed ID: 24307660
[TBL] [Abstract][Full Text] [Related]
37. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation.
Mohty M; de Lavallade H; Faucher C; Bilger K; Vey N; Stoppa AM; Gravis G; Coso D; Viens P; Gastaut JA; Blaise D
Bone Marrow Transplant; 2004 Sep; 34(6):527-30. PubMed ID: 15286687
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.
Mochizuki K; Kikuta A; Ito M; Sano H; Akaihata M; Kobayashi S; Ohto H; Hosoya M
Clin Transplant; 2011; 25(6):892-7. PubMed ID: 21070366
[TBL] [Abstract][Full Text] [Related]
39. [Intestinal infection by cytomegalovirus in kidney transplantation: diagnostic difficulty in the course of mycophenolate mofetil therapy].
Mugnani G; Bergami M; Lazzarotto T; Bedani PL
G Ital Nefrol; 2002; 19(4):483-4. PubMed ID: 12378698
[No Abstract] [Full Text] [Related]
40. Graft-versus-host disease: have we solved the problem?
Giralt S
J Clin Oncol; 2012 Sep; 30(26):3160-1. PubMed ID: 22869873
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
